[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362980-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362980-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","brca12-and-chek2-pathogenic-variants-in-urological-cancers-a-portuguese-single-center-experience","BRCA1/2 and CHEK2 Pathogenic Variants in Urological Cancers - A Portuguese Single-Center Experience","","Germline pathogenic variants in BRCA1, BRCA2, and CHEK2 are established cancer predisposition factors, yet their contribution across the full spectrum of urological cancers remains insufficiently defined. A retrospective descriptive study evaluated patients with urological cancers testing positive for BRCA1/2 or CHEK2 gPVs from a Portuguese hereditary cancer clinic, summarizing clinicopathologic features and overall survival using Kaplan-Meier and log-rank methods. Results included 47 families with 50 affected patients, founder-variant findings, and generally favorable CHEK2-associated outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/brca12-and-chek2-pathogenic-variants-in-urological-cancers-a-portuguese-single-center-experience/362980/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/brca12-and-chek2-pathogenic-variants-in-urological-cancers-a-portuguese-single-center-experience/362980.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary objective of the study?","Question",{"text":63,"@type":64},"To describe the spectrum and outcomes of urological cancers in BRCA1/2 and CHEK2 gPV carriers. Secondary aims included assessing overall survival and comparing age at diagnosis, stage, and survival by affected gene.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected and what was the study design?",{"text":68,"@type":64},"The study used a retrospective descriptive design including individuals diagnosed with urological cancers and testing positive for germline pathogenic variants in BRCA1, BRCA2, or CHEK2 identified at a hereditary cancer risk clinic.",{"name":70,"@type":61,"acceptedAnswer":71},"What were key findings regarding prostate cancer in BRCA1/2 carriers?",{"text":72,"@type":64},"Among prostate cancer patients carrying BRCA1/2 gPVs, all individuals with high-grade or metastatic disease carried BRCA2 gPVs, with younger diagnosis than expected. BRCA2 patients also showed more frequent co-diagnoses of other cancers, especially male breast cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362980,1790212851,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Review began 02/08/2026  \nReview ended 03/06/2026  \nPublished 03/10/2026  \n© Copyright 2026  \nQuinto Pereira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CCBY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.105002  \nOpen Access Original Article  \nBRCA1/2 and CHEK2 Pathogenic Variants in Urological Cancers: A Portuguese Single-Center Experience  \nMargarida Quinto Pereira 1, Isália Miguel 1 , Sofia Fragoso 2, Teresa Duarte 2, Sidónia Santos 2, Paula Rodrigues 3 , Carolina Pereira 1, Fátima Vaz 1  \n1. Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PRT 2. Molecular Pathobiology Research Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PRT 3. Familial Cancer Clinic Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PRT  \nCorresponding author: Margarida Quinto Pereira, [margaridaquinto@gmail.com](margaridaquinto@gmail.com)  \nAbstract  \nBackground  \nGermline pathogenic variants (gPVs) in BRCA1, BRCA2, and CHEK2 are well‑established cancer predisposition factors of prostate cancer. However, their contribution across the full spectrum of urological cancers remains insufficiently characterized.  \nThe primary objective was to describe the spectrum and outcomes of urological cancers in BRCA1/2 and CHEK2 gPV carriers, while secondary objectives were to assess overall survival (OS) and compare age at diagnosis, stage, and survival outcome by gene affected.  \nMethods  \nThis is a retrospective descriptive study including patients diagnosed with urological cancers and testing positive for gPVs in BRCA1, BRCA2, or CHEK2, identified at the Hereditary Cancer Risk Clinic of the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) . Familial and individual files were  \nsystematically reviewed to identify individuals with urological malignancies carrying gPVs. Descriptive statistics were used to summarize clinicopathologic characteristics. Survival outcomes were estimated using the Kaplan-Meier method and log-rank test for comparisons between groups, with p\u003C0 .05 considered  \nstatistically significant.  \nResults  \nA total of 968 BRCA1/2 or CHEK2 families were identified, of which 47 included 50 patients with urological cancer and a gPV in the genes of interest. Among BRCA1/2 carriers, BRCA2 was the most frequently affected gene (37 patients), with the BRCA2 Portuguese founder variant (c.156_ 157insAlu) identified in 23. 1% of  \ncases.  \nAmong prostate cancer patients carrying BRCA1/2 gPVs, all individuals with high-grade or metastatic disease carried BRCA2 gPVs. These patients were diagnosed at a younger age than either what is expected from the general population or patients with BRCA1-associated prostate cancer in this study. Also, BRCA2 prostate cancer patients were more frequently diagnosed with other cancers, with male breast cancer being the most frequent (32%) . Regarding family history, breast cancer was the most common malignancy observed (71% in BRCA1 and 74% in BRCA2 families), followed by other cases of prostate cancer (42% in BRCA1 vs. 34% in BRCA2) .  \nThe median OS among prostate cancer patients with advanced disease was 38 months (95% CI: 5.6-70.3), with no statistically significant difference between BRCA1 and BRCA2 carriers (p=0 .408) .  \nAll renal cancer patients with BRCA gPVs were female, had a personal history of breast cancer, and presented clear cell histology. Among urothelial cancer patients, one carried a BRCA1 gPV, and six carried BRCA2 gPVs. Most presented with non-muscle‑invasive bladder cancer (71 .4%), except for two BRCA2  \ncarriers who had advanced disease.  \nCHEK2‑associated urological cancers included renal cancer (n=1) and prostate cancer (n=5), all of which showed favorable outcomes. No testicular cancers were identifie","cbCaidHI3s2ZZZdN","https://ap.wps.com/l/cbCaidHI3s2ZZZdN","pdf",704926,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the primary objective of the study?\",\"answer\":\"To describe the spectrum and outcomes of urological cancers in BRCA1/2 and CHEK2 gPV carriers. Secondary aims included assessing overall survival and comparing age at diagnosis, stage, and survival by affected gene.\"},{\"question\":\"How were patients selected and what was the study design?\",\"answer\":\"The study used a retrospective descriptive design including individuals diagnosed with urological cancers and testing positive for germline pathogenic variants in BRCA1, BRCA2, or CHEK2 identified at a hereditary cancer risk clinic.\"},{\"question\":\"What were key findings regarding prostate cancer in BRCA1/2 carriers?\",\"answer\":\"Among prostate cancer patients carrying BRCA1/2 gPVs, all individuals with high-grade or metastatic disease carried BRCA2 gPVs, with younger diagnosis than expected. BRCA2 patients also showed more frequent co-diagnoses of other cancers, especially male breast cancer.\"}]","BRCA1/2 and CHEK2 Pathogenic Variants in Urological Cancers - A Portuguese Single-Center Experience | PDF",1790149577,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b213d8458977b97748bffcbd5704fd0.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d129df5d4328dc90087a06795119c7c.webp",982,1389,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddce598e8b4cd0fb89565d1c567d5d33.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9bb28d93e59808d2a158159f4b5cfb7.webp",980,1386]